CYTOKINETICS INC (CYTK) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Low Risk
Limited dilution potential
Last updated: May 05, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares
Recent Dilution: 5.64% (2 years)
Historical Dilution Factor: minimal recent dilution
Outstanding Shares
120M
Potential Supply
0
Additional shares possible
Splits
None
Past 2 years

Summary

CYTK currently has 124M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.64% over the past 2 years.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 05, 2026

10-Q filing | 124.4M shares outstanding

120M 0
Nov 05, 2025

10-Q filing | 122.3M shares outstanding

120M 0
May 06, 2025

10-Q filing | 119.4M shares outstanding

120M 0
Feb 27, 2025

10-K filing | 118.4M shares outstanding

120M 0
Nov 07, 2024

10-Q filing | 118.0M shares outstanding

120M 0
Aug 09, 2024

10-Q filing | 117.7M shares outstanding

120M 0
May 10, 2024

10-Q filing | 104.9M shares outstanding

100M 0
Feb 28, 2024

10-K filing | 103.0M shares outstanding

100M 0
Nov 03, 2023

10-Q filing | 98.1M shares outstanding

98M 0
Aug 03, 2023

10-Q filing | 96.0M shares outstanding

96M 0
May 05, 2023

10-Q filing | 95.6M shares outstanding

96M 0
Mar 01, 2023

10-K filing | 95.2M shares outstanding

95M 0
Nov 04, 2022

10-Q filing | 94.6M shares outstanding

95M 0
Aug 05, 2022

10-Q filing | 94.1M shares outstanding

94M 0
May 06, 2022

10-Q filing | 85.7M shares outstanding

86M 0
Feb 25, 2022

10-K filing | 84.9M shares outstanding

85M 0
Dec 20, 2021

8-K filing: Cytokinetics entered into a License and Collaboration Agreement with Ji Xing Pharmaceuticals Limited, granting Ji Xing an exclusive license to develop and commercialize Cytokinetics' proprietary small molecule cardiac sarcomere activator known as omecamtiv mecarbil in the greater China region and also entered into Common Stock Purchase Agreements with RTW Investors for the sale and issuance of 511,182 shares of Cytokinetics common stock at $39.125 per share. ($20.0M proceeds)

84M 0
Nov 05, 2021

10-Q filing | 83.9M shares outstanding

84M 0
Aug 06, 2021

10-Q filing | 83.5M shares outstanding

84M 0
May 07, 2021

10-Q filing | 71.7M shares outstanding

72M 0
Feb 26, 2021

10-K filing | 71.1M shares outstanding

71M 0
Nov 06, 2020

10-Q filing | 70.8M shares outstanding

71M 0
Aug 07, 2020

10-Q filing | 70.5M shares outstanding

71M 0
May 08, 2020

10-Q filing | 59.5M shares outstanding

59M 0
Mar 04, 2020

10-K filing | 59.5M shares outstanding

59M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime